← All candidates
250 insider filings on record.
250 filings on record.
ALNYALNYLAM PHARMACEUTICALS, INC.
NasdaqGS · Healthcare · $37.13B
$239.36
+0.46% · Sep 16
250 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 217 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$37.13B
Float
132.9M
100% public
Short % float
Pro
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
245 more transactions on Pro →Context
Wall St
$434.72 avg target
+81.6% vs today · 25 analysts · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26$1.99 act+$0.52
Q4 '25$1.25 act−$0.25
Q3 '25$2.90 act+$1.15
Q2 '25$0.32 act+$0.17
Coverage
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?Zacks · 07-06What Offers Alnylam Pharmaceuticals (ALNY) Sustained Long-Term Growth?Insider Monkey · 07-03Komodo Expands Strategic Partnership with Alnylam Pharmaceuticals, Inc. (ALNY)Insider Monkey · 07-02Alnylam Pharmaceuticals, Inc. (ALNY) and GENESIS Pharma Expand Commercial PartnershipInsider Monkey · 06-23
The file stays open
250 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice